ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Teva Pharmaceutical Industries and MODAG side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Teva Pharmaceutical IndustriesMODAG
studies on the registry6716
open to participants now63
phase 3 studies under way20
reach primary completion within a year33
programswith a study of their own in two years42

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseTeva Pharmaceutical IndustriesMODAG
Phase 100%

MODAG: 2 of its 2 programs at phase 1

  1. MODAG-009early phase 1
  2. MODAG-005early phase 1
100%
Phase 2

Teva Pharmaceutical Industries: 1 of its 4 programs at phase 2

  1. emrusolminphase 2
25%
00%
Phase 3

Teva Pharmaceutical Industries: 2 of its 4 programs at phase 3

  1. TEV-53408phase 3
  2. tapinarofphase 3
50%
00%
Approved, new studies

Teva Pharmaceutical Industries: 1 of its 4 programs at approved, new studies

  1. deutetrabenazineapproved, new study
25%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Teva Pharmaceutical Industries1 readouts · 0 phase 3··

Teva Pharmaceutical Industries, Jan ’27: 1 program whose next study reaches primary completion

  1. emrusolminphase 2 · Jan 15 · NCT07674940
·········
MODAG2 readouts · 0 phase 3······

MODAG, May ’27: 1 program whose next study reaches primary completion

  1. MODAG-009early phase 1 · May 0 · NCT07640555
·

MODAG, Jul ’27: 1 program whose next study reaches primary completion

  1. MODAG-005early phase 1 · Jul 0 · NCT07640542
···
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Teva Pharmaceutical Industries

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 0

None

MODAG

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionTeva Pharmaceutical IndustriesMODAG
Multiple System Atrophyboth · compare here

Teva Pharmaceutical Industries in Multiple System Atrophy: 1 program

  1. emrusolminphase 2

Their studies: Teva Pharmaceutical Industries’ studies of Multiple System Atrophy in search

MODAG in Multiple System Atrophy: 1 program

  1. MODAG-009early phase 1

Their studies: MODAG’s studies of Multiple System Atrophy in search

Parkinson Diseaseboth · compare here

Teva Pharmaceutical Industries in Parkinson Disease: 1 program

  1. emrusolminphase 2

Their studies: Teva Pharmaceutical Industries’ studies of Parkinson Disease in search

MODAG in Parkinson Disease: 1 program

  1. MODAG-005early phase 1

Their studies: MODAG’s studies of Parkinson Disease in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Teva Pharmaceutical Industries 2 of 4 · MODAG 0 of 2 programs (2 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.